A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04777175

Enrollment

186

Registered

2021-03-02

Start date

2023-01-01

Completion date

2025-01-12

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Interventions

DRUGimmunity therapy

The patient receives immunotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation

Exclusion criteria

* The patient is diagnosed with small cell lung cancer

Design outcomes

Primary

Measure	Time frame	Description
PFS	January 2021- January 2021 (1 year)	Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026